MedTrace Logo

Vitamin D and Hereditary Haemorrhagic Telangiectasia

NCT03981562 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-06-11

No results posted yet for this study

Summary

The study aims to assess whether supplementing vitamin D in patients diagnosed with Hereditary Haemorrhagic Telangiectasia (HHT) will decrease the frequency and severity of nosebleeds these patients experience. It is hypothesized that the larger the dose of daily vitamin D given to the patients, the less frequent and less severe the nosebleeds will be.

Conditions

  • Hereditary Haemorrhagic Telangiectasia

Interventions

DRUG

Vit D

Patients will take an oral vitamin D supplement once a day for 6 months.

DRUG

Placebo Oral Tablet

Patients will take a placebo oral tablet once a day for 6 months.

Sponsors & Collaborators

  • St. Paul's Hospital, Canada

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2020-07-01
Completion
2020-09-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03981562 on ClinicalTrials.gov